Abortion Medication to Be Introduced in Q1 Next Year... Approval of "Mifgimiso" Is the First Hurdle (Comprehensive)
MFDS Says "Hyundai Pharm's Third Approval Application Largely Reviewed"
Key Challenges Remain: Importation, Quality Inspection, and Securing Adequate Supply After Approval
The government has announced its goal to introduce medication for pregnancy termination in Korea within the first quarter of next year. However, as the product licensing review is still ongoing, and additional steps such as import procedures, quality inspections, and securing available quantities must follow even after approval, there remain considerable variables before the medication can reach the market.
Won Minkyeong, Minister of Gender Equality and Family, is making a presentation on the plan to formally introduce abortion medication at the Seoul Government Complex in Jongno-gu, Seoul, on the 16th. 2026.9.16 Photo by Yongjun Cho
View original imageShin Junsu, Director General of the Drug Safety Bureau at the Ministry of Food and Drug Safety, stated at a briefing on the 16th, "(The pregnancy termination medication being considered for introduction in Korea) filed for approval in December 2024, and much of the approval and review process is already underway," adding, "Certain aspects, including the risk management plan, still require further review for approval."
The product in question is 'Mifjimiso,' an oral pregnancy termination medication developed by Hyundai Pharm. It is provided as a combi-pack containing one 200mg mifepristone tablet and four 200mcg misoprostol tablets. Hyundai Pharm submitted the third application for product approval to the Ministry of Food and Drug Safety in December 2024.
The Ministry of Food and Drug Safety plans to review supplementary materials submitted by the pharmaceutical manufacturer and will assess safety, efficacy, and quality before making a decision on approval. In particular, the risk management plan for monitoring adverse events after the product is released will be included in the review process.
Even after approval is granted, domestic distribution will not start immediately. Director Shin explained, "After approval, the company must go through import procedures," and noted that label preparation, safety and quality inspections, as well as securing sufficient quantity, are required steps.
Therefore, the government's target to introduce the product within the first quarter of next year depends not only on the review process by the Ministry of Food and Drug Safety but also on the timely preparations by the pharmaceutical company. Director Shin emphasized, "We will work closely with the company to ensure introduction within the first quarter of next year if at all possible."
The approval application for Mifjimiso is based on clinical trial data for use up to nine weeks of pregnancy. The Ministry of Food and Drug Safety is conducting its review based on this data. Director Shin explained, "The indication for use up to nine weeks is based on the results of clinical trials submitted for this product."
In the initial phase after introduction, the medication will be prescribed and dispensed directly by physicians at medical institutions for two years. The standard for prescribing physicians is being considered as ensuring medical competency to assess gestational age and detect potential ectopic pregnancy, rather than simply holding a specialist qualification.
Kwak Soonheon, Director of Health and Medical Policy at the Ministry of Health and Welfare, stated, "As the Criminal Act and the Mother and Child Health Act have not yet been revised, allowing pharmacists to dispense the product could lead to issues based on Ministry of Justice interpretations. For now, we intend to ensure safety by limiting dispensing to direct physician administration for two years." Kim Hyunsook, Director of Population and Children Policy, added, "The most crucial factor is having the competency to determine pregnancy, gestational week, ectopic pregnancy, and contraindications to medication use. We will continue consultation with the medical community on this matter."
Questions such as whether the medication will be included in national health insurance coverage and the final pricing remain undecided. The government maintains that the pharmaceutical manufacturer must apply for coverage before this can be reviewed. If no such application is made, the medication could be launched as a non-covered product, in which case the government will monitor, compare, and disclose pricing information by medical institution.
After product approval, the government plans to establish specific standard clinical guidelines in consultation with the Obstetrics and Gynecology Society and the broader healthcare community. According to the current approval application, the process involves taking mifepristone, followed by misoprostol within 24 to 48 hours, and then confirming results at a medical institution within 7 to 14 days.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Director Shin stated, "Some areas, such as the risk management plan, require supplemental review," adding, "We will thoroughly review the relevant materials with public safety as the top priority."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.